HIV Research Today is a free monthly online journal that collates and summarizes the latest research about HIV, including details on human immunodeficiency virus, testing, treatment, prevention, vaccines, aids.

Volume 6 (2009), Issue 5 (May)

1. PPARalpha and PPARgamma attenuate HIV-induced dysregulation of tight junction proteins by modulations of matrix metalloproteinase and proteasome activities.
   FASEB J, 23(5): 1596-606. [Abstract] [Full-text]
2. Viral fitness implications of variation within an immunodominant CD8+ T-cell epitope of HIV-1.
   Virology, 388(1): 137-46. [Abstract] [Full-text]
3. Impact of a single amino acid in the variable region 2 of the Old World monkey TRIM5alpha SPRY (B30.2) domain on anti-human immunodeficiency virus type 2 activity.
   Virology, 388(1): 160-8. [Abstract] [Full-text]
4. Characterization of HIV-2 chimeric viruses unable to use CCR5 and CXCR4 coreceptors.
   Virus Res, 142(1): 41-50. [Abstract] [Full-text]
5. IgE-FcepsilonRI interactions determine HIV coreceptor usage and susceptibility to infection during ontogeny of mast cells.
   J Immunol, 182(10): 6401-9. [Abstract] [Full-text]
6. M1 and M2a polarization of human monocyte-derived macrophages inhibits HIV-1 replication by distinct mechanisms.
   J Immunol, 182(10): 6237-46. [Abstract] [Full-text]
7. Cutting Edge: Unusual NK cell responses to HIV-1 peptides are associated with protection against maternal-infant transmission of HIV-1.
   J Immunol, 182(10): 5914-8. [Abstract] [Full-text]
8. Optimal control of HIV-virus dynamics.
   Ann Biomed Eng, 37(6): 1251-61. [Abstract] [Full-text]
9. Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10.
   Proc Natl Acad Sci U S A, 106(18): 7385-90. [Abstract] [Full-text]
10. Microbial translocation, the innate cytokine response, and HIV-1 disease progression in Africa.
    Proc Natl Acad Sci U S A, 106(16): 6718-23. [Abstract] [Full-text]
11. Decreased risk of congenital cytomegalovirus infection in children born to HIV-1-infected mothers in the era of highly active antiretroviral therapy.
    Clin Infect Dis, 48(11): 1516-25. [Abstract] [Full-text]
12. HIV-1 superinfection in an HIV-2-infected woman with subsequent control of HIV-1 plasma viremia.
    Clin Infect Dis, 48(11): e117-20. [Abstract] [Full-text]
13. HIV-1 associated dementia: update on pathological mechanisms and therapeutic approaches.
    Curr Opin Neurol, 22(3): 315-20. [Abstract] [Full-text]
14. Synthesis and antiviral activity of 7-benzyl-4-hydroxy-1,5-naphthyridin-2(1H)-one HIV integrase inhibitors.
    J Med Chem, 52(9): 2754-61. [Abstract] [Full-text]
15. Cytokine changes during rituximab therapy in HIV-associated multicentric Castleman disease.
    Blood, 113(19): 4521-4. [Abstract] [Full-text]
16. Clinical relevance of substitutions in the connection subdomain and RNase H domain of HIV-1 reverse transcriptase from a cohort of antiretroviral treatment-naïve patients.
    Antiviral Res, 82(3): 115-21. [Abstract] [Full-text]
17. Molecular Interactions between HIV-1 integrase and the two viral DNA ends within the synaptic complex that mediates concerted integration.
    J Mol Biol, 389(1): 183-98. [Abstract] [Full-text]
18. Maraviroc: perspectives for use in antiretroviral-naive HIV-1-infected patients.
    J Antimicrob Chemother, 63(6): 1087-96. [Abstract] [Full-text]
19. Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort.
    J Antimicrob Chemother, 63(6): 1251-5. [Abstract] [Full-text]
20. White matter changes in HIV-1 infected brains: a combined gross anatomical and ultrastructural morphometric investigation of the corpus callosum.
    Clin Neurol Neurosurg, 111(5): 422-9. [Abstract] [Full-text]
21. Tissue-specific sequence alterations in the human immunodeficiency virus type 1 envelope favoring CCR5 usage contribute to persistence of dual-tropic virus in the brain.
    J Virol, 83(11): 5430-41. [Abstract] [Full-text]
22. Comparison of human and rhesus macaque T-cell responses elicited by boosting with NYVAC encoding human immunodeficiency virus type 1 clade C immunogens.
    J Virol, 83(11): 5881-9. [Abstract] [Full-text]
23. Optimal translation initiation enables Vif-deficient human immunodeficiency virus type 1 to escape restriction by APOBEC3G.
    J Virol, 83(11): 5956-60. [Abstract] [Full-text]
24. Evidence that productive human immunodeficiency virus type 1 assembly can occur in an intracellular compartment.
    J Virol, 83(11): 5375-87. [Abstract] [Full-text]
25. CCR5- and CXCR4-tropic subtype C human immunodeficiency virus type 1 isolates have a lower level of pathogenic fitness than other dominant group M subtypes: implications for the epidemic.
    J Virol, 83(11): 5592-605. [Abstract] [Full-text]
26. The interaction of monocyte chemoattractant protein-1 and tumour necrosis factor-alpha in Mycobacterium tuberculosis-induced HIV-1 replication at sites of active tuberculosis.
    Scand J Immunol, 69(6): 516-20. [Abstract] [Full-text]
27. Infants with late breast milk acquisition of HIV-1 generate interferon-gamma responses more rapidly than infants with early peripartum acquisition.
    Clin Exp Immunol, 156(3): 511-7. [Abstract] [Full-text]
28. Is the high virulence of HIV-1 an unfortunate coincidence of primate lentiviral evolution?
    Nat Rev Microbiol, 7(6): 467-76. [Abstract] [Full-text]
29. The human P(k) histo-blood group antigen provides protection against HIV-1 infection.
    Blood, 113(20): 4980-91. [Abstract] [Full-text]
30. Assessment of sensitivity and specificity of first, second, and third generation EIA for the detection of antibodies to HIV-1 in oral fluid.
    J Virol Methods, 159(1): 119-21. [Abstract] [Full-text]
31. Quantitation of human immunodeficiency virus type 1 viral load in plasma using reverse transcriptase activity assay at a district hospital laboratory in Botswana: a decentralization pilot study.
    J Virol Methods, 159(1): 93-7. [Abstract] [Full-text]
32. A neutralization assay for HIV-2 based on measurement of provirus integration by duplex real-time PCR.
    J Virol Methods, 159(1): 40-6. [Abstract] [Full-text]
33. Detection of HIV-1 in alternative specimen types using the APTIMA HIV-1 RNA Qualitative Assay.
    J Virol Methods, 159(1): 10-4. [Abstract] [Full-text]
34. HIV-1 and influenza antibodies: seeing antigens in new ways.
    Nat Immunol, 10(6): 573-8. [Abstract] [Full-text]
35. Lentivirus-mediated RNA interference reversing the drug-resistance in MDR1 single-factor resistant cell line K562/MDR1.
    Leuk Res, 33(8): 1114-9. [Abstract] [Full-text]
36. The RNA recognition mechanism of human immunodeficiency virus (HIV) type 2 NCp8 is different from that of HIV-1 NCp7.
    Biochemistry, 48(20): 4314-23. [Abstract] [Full-text]
37. Human immunodeficiency virus integration efficiency and site selection in quiescent CD4+ T cells.
    J Virol, 83(12): 6222-33. [Abstract] [Full-text]
38. Simultaneous cell-to-cell transmission of human immunodeficiency virus to multiple targets through polysynapses.
    J Virol, 83(12): 6234-46. [Abstract] [Full-text]
39. Idiopathic AIDS enteropathy and treatment of gastrointestinal opportunistic pathogens.
    Gastroenterology, 136(6): 1952-65. [Abstract] [Full-text]
40. Primary human immunodeficiency virus type 1-specific CD8+ T-cell responses induced by myeloid dendritic cells.
    J Virol, 83(12): 6288-99. [Abstract] [Full-text]
41. Potential role of interleukin-18 in the immunopathogenesis of AIDS: involvement in fratricidal killing of NK cells.
    J Virol, 83(12): 5999-6010. [Abstract] [Full-text]
42. Monotypic human immunodeficiency virus type 1 genotypes across the uterine cervix and in blood suggest proliferation of cells with provirus.
    J Virol, 83(12): 6020-8. [Abstract] [Full-text]
43. Predictive value of pharmacokinetics-adjusted phenotypic susceptibility on response to ritonavir-enhanced protease inhibitors (PIs) in human immunodeficiency virus-infected subjects failing prior PI therapy.
    Antimicrob Agents Chemother, 53(6): 2335-41. [Abstract] [Full-text]
44. Genital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected women.
    Antimicrob Agents Chemother, 53(6): 2367-74. [Abstract] [Full-text]
45. Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
    Antimicrob Agents Chemother, 53(6): 2424-31. [Abstract] [Full-text]
46. Genetic characterization of HIV-1 strains in Togo reveals a high genetic complexity and genotypic drug-resistance mutations in ARV naive patients.
    Infect Genet Evol, 9(4): 646-52. [Abstract] [Full-text]
47. Distribution of CCR5 genotypes and HLA Class I B alleles in HIV-1 infected and uninfected injecting drug users from Rio de Janeiro, Brazil.
    Infect Genet Evol, 9(4): 638-42. [Abstract] [Full-text]
48. Genetic characterization of HIV-1 BC recombinants and evolutionary history of the CRF31_BC in Southern Brazil.
    Infect Genet Evol, 9(4): 474-82. [Abstract] [Full-text]
49. The rise and fall of K65R in a Portuguese HIV-1 Drug Resistance database, despite continuously increasing use of tenofovir.
    Infect Genet Evol, 9(4): 683-8. [Abstract] [Full-text]
50. Highly divergent subtypes and new recombinant forms prevail in the HIV/AIDS epidemic in Angola: new insights into the origins of the AIDS pandemic.
    Infect Genet Evol, 9(4): 672-82. [Abstract] [Full-text]
51. A novel sorting strategy of trichosanthin for hijacking human immunodeficiency virus type 1.
    Biochem Biophys Res Commun, 384(3): 347-51. [Abstract] [Full-text]
52. Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients.
    J Acquir Immune Defic Syndr, 51(2): 163-74. [Abstract] [Full-text]
53. The nucleoside backbone affects durability of efavirenz- or nevirapine-based highly active antiretroviral therapy in antiretroviral-naive individuals.
    J Acquir Immune Defic Syndr, 51(2): 140-6. [Abstract] [Full-text]
54. Survival of HIV-1 infected multidrug-resistant patients recycling enfuvirtide after a previous failure.
    J Acquir Immune Defic Syndr, 51(2): 179-84. [Abstract] [Full-text]
55. The differential binding and activity of PRO 2000 against diverse HIV-1 envelopes.
    J Acquir Immune Defic Syndr, 51(2): 125-9. [Abstract] [Full-text]
56. Innate factors in human breast milk inhibit cell-free HIV-1 but not cell-associated HIV-1 infection of CD4+ cells.
    J Acquir Immune Defic Syndr, 51(2): 117-24. [Abstract] [Full-text]
57. Lipodystrophy and metabolic disorders in HIV-1-infected adults on 4- to 9-year antiretroviral therapy in Senegal: a case-control study.
    J Acquir Immune Defic Syndr, 51(2): 224-30. [Abstract] [Full-text]
58. Mitochondrial DNA haplogroups influence lipoatrophy after highly active antiretroviral therapy.
    J Acquir Immune Defic Syndr, 51(2): 111-6. [Abstract] [Full-text]
59. TAT-mediated peroxiredoxin 5 and 6 protein transduction protects against high-glucose-induced cytotoxicity in retinal pericytes.
    Life Sci, 84(23): 857-64. [Abstract] [Full-text]
60. HIV-1 transactivator protein induction of suppressor of cytokine signaling-2 contributes to dysregulation of IFN{gamma} signaling.
    Blood, 113(21): 5192-201. [Abstract] [Full-text]
61. Osteonecrosis of the femoral head in patients with type 1 human immunodeficiency virus infection: clinical analysis and review.
    Clin Rheumatol, 28(7): 815-23. [Abstract] [Full-text]
62. Presence of a multidrug-resistance mutation in an HIV-2 variant infecting a treatment-naive individual in Caio, Guinea Bissau.
    Clin Infect Dis, 48(12): 1790-3. [Abstract] [Full-text]
63. Desensitization to type I interferon in HIV-1 infection correlates with markers of immune activation and disease progression.
    Blood, 113(22): 5497-505. [Abstract] [Full-text]
64. Cross-cohort heterogeneity encountered while validating a model for HIV disease progression among antiretroviral initiators.
    J Clin Epidemiol, 62(7): 729-37. [Abstract] [Full-text]

© 2004-2010 HIV Research Today. All Rights Reserved.